A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in Subjective Tinnitus
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
Price : $35 *
At a glance
- Drugs AUT 00063 (Primary)
- Indications Tinnitus
- Focus Therapeutic Use
- Acronyms QUIET-1
- Sponsors Autifony Therapeutics
- 22 Mar 2017 This trial has been discontinued in UK (End date:2015-10-08) as per European ClinicalTrials database record.
- 30 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.